Sign up
Pharma Capital

INmune Bio to begin enrolling patients in Alzheimer's study by mid-summer

INmune Bio Inc (NASDAQ:INMB) CFO David Moss tells Proactive Investors the immunology biotech company is excited to begin enrolling patients in June or July for its Phase 1 study to treat Alzheimer's disease.

The California-based biotech's stock has jumped 20% in the last few days, having rung Nasdaq's closing bell to commemorate its recent IPO. Moss says increased media attention around the bell ceremony, or perhaps upcoming data on its other drug candidates may be helping to drive the stock.

 

View full INMB profile View Profile
View All

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.